One connector, four scholarly indexes, real DOIs and legal free PDFs. Works in Claude and ChatGPT.
Paste it into Claude or ChatGPT as a custom connector. 3-day free trial.
Steven R. Ytterberg, Deepak L. Bhatt, Ted R. Mikuls, Gary G. Koch, Roy Fleischmann, Jose L. Rivas, Rebecca Germino, Sujatha S. Menon, Yanhui Sun, Cunshan Wang and 3 more
BACKGROUND: Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving tofacitinib as compared with a tumor necrosis factor (TNF) inhibitor. METHODS: We conducted a randomized, open-label, noninferiority, postauthorization, safety end-point trial involving patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor. Patients were randomly assigned in a 1:1:1 ratio to receive tofacitinib at a dose of 5 mg or 10 mg twice daily or a TNF inhibitor. The coprimary end points were adjudicated MACE and cancers, excluding nonmelanoma skin cancer. The noninferiority of tofacitinib would be shown if the upper boundary of the two-sided 95% confidence interval for the hazard ratio was less than 1.8 for the combined tofacitinib doses as compared with a TNF inhibitor. RESULTS: A total of 1455 patients received tofacitinib at a dose of 5 mg twice daily, 1456 received tofacitinib at a dose of 10 mg twice daily, and 1451 received a TNF inhibitor. During a median follow-up of 4.0 years, the incidences of MACE and cancer were higher with the combined tofacitinib doses (3.4% [98 patients] and 4.2% [122 patients], respectively) than with a TNF inhibitor (2.5% [37 patients] and 2.9% [42 patients]). The hazard ratios were 1.33 (95% confidence interval [CI], 0.91 to 1.94) for MACE and 1.48 (95% CI, 1.04 to 2.09) for cancers; the noninferiority of tofacitinib was not shown. The incidences of adjudicated opportunistic infections (including herpes zoster and tuberculosis), all herpes zoster (nonserious and serious), and adjudicated nonmelanoma skin cancer were higher with tofacitinib than with a TNF inhibitor. Efficacy was similar in all three groups, with improvements from month 2 that were sustained through trial completion. CONCLUSIONS: In this trial comparing the combined tofacitinib doses with a TNF inhibitor in a cardiovascular risk-enriched population, risks of MACE and cancers were higher with tofacitinib and did not meet noninferiority criteria. Several adverse events were more common with tofacitinib. (Funded by Pfizer; ORAL Surveillance ClinicalTrials.gov number, NCT02092467.).
Formatted from the source metadata, not typed by hand. For a whole reference list, use the citation generator or ask your assistant through Find Research.
Ytterberg, S. R., Bhatt, D. L., Mikuls, T. R., Koch, G. G., Fleischmann, R., Rivas, J. L., Germino, R., Menon, S. S., Sun, Y., Wang, C., Shapiro, A. B., Kanik, K. S., & Connell, C. A. (2022). Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. New England Journal of Medicine, 386(4), 316–326. https://doi.org/10.1056/nejmoa2109927
Ytterberg, Steven R., et al. "Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis." New England Journal of Medicine, vol. 386, no. 4, 2022, pp. 316–326, https://doi.org/10.1056/nejmoa2109927.
Ytterberg, Steven R., Deepak L. Bhatt, Ted R. Mikuls, Gary G. Koch, Roy Fleischmann, Jose L. Rivas, Rebecca Germino, et al. "Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis." New England Journal of Medicine 386, no. 4 (2022): 316–326. https://doi.org/10.1056/nejmoa2109927.
Ytterberg S. R., Bhatt D. L., Mikuls T. R. [и др.] Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis // New England Journal of Medicine. — 2022. — Vol. 386, № 4. — P. 316–326. — URL: https://doi.org/10.1056/nejmoa2109927
@article{ytterberg2022cardiovascular,
title = {{Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis}},
author = {Steven R. Ytterberg and Deepak L. Bhatt and Ted R. Mikuls and Gary G. Koch and Roy Fleischmann and Jose L. Rivas and Rebecca Germino and Sujatha S. Menon and Yanhui Sun and Cunshan Wang and Andrea B. Shapiro and Keith S. Kanik and Carol A. Connell},
journal = {New England Journal of Medicine},
year = {2022},
volume = {386},
number = {4},
pages = {316--326},
doi = {10.1056/nejmoa2109927},
url = {https://doi.org/10.1056/nejmoa2109927}
}TY - JOUR AU - Ytterberg, Steven R. AU - Bhatt, Deepak L. AU - Mikuls, Ted R. AU - Koch, Gary G. AU - Fleischmann, Roy AU - Rivas, Jose L. AU - Germino, Rebecca AU - Menon, Sujatha S. AU - Sun, Yanhui AU - Wang, Cunshan AU - Shapiro, Andrea B. AU - Kanik, Keith S. AU - Connell, Carol A. TI - Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis JO - New England Journal of Medicine VL - 386 IS - 4 SP - 316 EP - 326 PY - 2022 DA - 2022/01/26 DO - 10.1056/nejmoa2109927 UR - https://doi.org/10.1056/nejmoa2109927 ER -
Add Find Research to Claude or ChatGPT and ask in plain language. The assistant reads this record, finds the papers around it and cites only what it actually found:
Setup takes about a minute: add the connector, then start the free trial.
Record from OpenAlex; open-access location from Unpaywall and the indexes. Find Research links only to legal copies.